|Detection of SLAM/CD150 in Human Lymphocytes by Flow Cytometry. Human whole blood lymphocytes were stained with Sheep Anti-Human SLAM/CD150 Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF164, filled histogram) or isotype control antibody (Catalog # 5-001-A, open histogram), followed by NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # NL010).|
|Detection of Human SLAM/CD150 by Western Blot. Western blot shows lysates of Jurkat human acute T cell leukemia cell line and Nalm‑6 human Pre‑B acute lymphocytic leukemia cell line. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human SLAM/CD150 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF164) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for SLAM/CD150 at approximately 70 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.|
SLAM (also IPO-3 and CD150) is a 70‑80 kDa member of the CD2 family of molecules. It is a costimulatory receptor that mediates T cell activation via SAP. SLAM is found on B cells, dendritic cells, macrophages, stem cells and Th1 T cells. SLAM engages in homophilic interactions. Mature human SLAM is 315 amino acids (aa) in length. It is a type I transmembrane glycoprotein whose extracellular domain contains one V-type and one C2-type Ig-like domain (aa 21‑237). There is a 77 aa SH2‑binding cytoplasmic domain. Four potential splice variants are suggested. One shows a deletion of aa 234‑263 (potentially soluble), while three others show aa substitutions; i.e.‑a ten aa substitution for aa 289‑335, a six aa substitution for aa 264‑335 and a 20 aa substitution for aa 125‑335 (potentially soluble). Over aa 1‑236, human SLAM shares 60% aa identity with mouse SLAM.